drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous CAR T cells)
drug_description
Autologous, gene-modified CAR T-cell therapy; patient T cells engineered to express a chimeric antigen receptor targeting B-lineage antigens (e.g., CD19 and CD22) to induce targeted cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene-modified to express a chimeric antigen receptor targeting B-lineage antigens (e.g., CD19 and CD22). Antigen binding activates the CAR signaling domains, driving T-cell activation, expansion, cytokine release, and perforin/granzyme-mediated cytotoxic killing of malignant B cells.
drug_name
CAR2219
nct_id_drug_ref
NCT06911710